Drug intelligence / Profile preview

NC-SER

Development stage: Preclinical
Lead developer: Medlab Clinical
Modality: Nanoparticles → Drug Delivery Systems
Administration: Sublingual

Overview

NC-SER is a preclinical drug candidate developed by Medlab Clinical (now Medlab Group) that utilizes the proprietary NanoCelle drug delivery platform to deliver growth hormone (somatropin) sublingually. The NanoCelle technology creates micellar nanoparticles that enhance the solubility and absorption of the hormone through the oral mucosa, allowing it to enter the bloodstream directly and bypass the gastrointestinal tract and first-pass metabolism. NC-SER is being developed for indications such as muscular hypertrophy and weight loss, providing a potentially more convenient and non-invasive alternative to traditional injectable growth hormone therapies.

Other names: NanoCelle Growth Hormone

Targets

GHR (Growth hormone receptor)

Beyond the preview

Go deeper on NC-SER.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NC-SER.

Explore the full profile